Please login to the form below

Not currently logged in
Email:
Password:

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

Swedish Orphan Biovitrum Sobi

Sobi (Swedish Orphan Biovitrum) has opened doors on its new European and Benelux office in Brussels.

The company said the move was a reflection of its expanding international presence and would act as an operational hub for its business.

Hege Hellstrom, president EMENAR at Sobi, said: "Brussels provides an ideal location for our European operations. Being a company dedicated to rare diseases, Brussels is of vital importance to Sobi from a business, regulatory, policy and stakeholder interaction perspective.

“The Belgian authorities have also consistently been thought leaders in collaborative, cross-border approaches to access and availability of rare disease therapies for patients."

The rare disease-focused specialty pharmaceutical company has more than 600 employees who concentrate primarily on its work in haemophilia, inflammation and genetic diseases.

In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1).

More recently the FDA this week began its review of the oral suspension formulation of Orfadin, and Sobi said a formal decision on the product from the US regulator is expected during the second quarter 2016.

Article by
Dominic Tyer

11th September 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics